AKT1 and cancer: Similarly, the degradation of AKT mediated by mTORC2 inhibition enhances FOXO nuclear retention and glucose output via the activation of PCK1 and G6Pase and the consequent upregulation of phosphoenolpyruvate carboxykinase 2 (PEPCK) in cancer cells [87].